AI Article Synopsis
- The study looked at patients with a serious infection called hVISA who were treated with a medicine called vancomycin and found that a lot of them (78%) didn't get better.
- Older patients and those with serious health problems had a harder time improving compared to younger and healthier patients.
- Researchers discovered that age and how severe the infection was played big roles in whether the treatment worked or not, suggesting doctors should pay extra attention to these factors when treating hVISA infections.
Article Abstract
The incidence of heterogeneous vancomycin-intermediate (hVISA) infection is increasing and is associated with vancomycin treatment failures. However, studies investigating the risk factors for treatment failure in hVISA infection are limited. Patients with hVISA bacteremia treated with vancomycin over 7 days between August 2008 and June 2020 were enrolled in this study. Clinical and microbiological characteristics were compared between vancomycin treatment failure and success groups to identify the risk factors for vancomycin treatment failure. Among the 180 patients with hVISA bacteremia, 102 patients treated with vancomycin over 7 days were included. Vancomycin treatment failed in 80 (78%) patients. Patients in the vancomycin treatment failure group were older ( < 0.001) and more frequently had solid cancer ( = 0.04) than those in the vancomycin treatment success group. Solid organ transplantation (SOT) was more frequent ( < 0.001) in the vancomycin treatment success group. The Charlson comorbidity index ( = 0.01) and Acute Physiology and Chronic Health Evaluation II scores ( < 0.001) were higher in the vancomycin treatment failure group. In multivariate analysis, independent risk factors for vancomycin treatment failure were old age and severity of bacteremia. SOT and vancomycin minimal inhibitory concentration (MIC) ≤ 1.0 mg/L using the broth microdilution (BMD) method were associated with successful vancomycin treatment. Old age and infection severity were independent risk factors for vancomycin treatment failure. Vancomycin MIC using the BMD method is an important risk factor for vancomycin treatment failure, and its use should be considered in hVISA bacteremia.IMPORTANCEIn this study, we assessed the clinical and microbiological characteristics of heterogeneous vancomycin-intermediated (hVISA) bacteremia and identified risk factors for vancomycin treatment failure. We found that advanced age and severity of infection were independent risk factors for vancomycin treatment failure. On the other hand, solid organ transplantation and a low vancomycin minimal inhibitory concentration were associated with successful vancomycin treatment. This study highlights the importance of vancomycin minimal inhibitory concentration in hVISA bacteremia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302031 | PMC |
| http://dx.doi.org/10.1128/spectrum.00333-24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vancomycin wound penetration in open-heart surgery patients receiving negative pressure wound therapy for deep sternal wound infection.
Ann Med
December 2025
Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic.
Introduction: It is hypothesized that systemically administered antibiotics penetrate wound sites more effectively during negative pressure wound therapy (NPWT). However, there is a lack of clinical data from patients who receive NPWT for deep sternal wound infection (DSWI) after open-heart surgery. Here, we evaluated vancomycin penetration into exudate in this patient group.
View Article and Find Full Text PDFPathogenic Burden, Antimicrobial Resistance Pattern and Clinical Outcome of Nosocomial Bloodstream Infections in Intensive Care Unit.
J Intensive Care Med
December 2024
Department of Critical Care and Anaesthesiology, All India Institute of Medical Sciences, Jodhpur, India.
Nosocomial bloodstream infections with multidrug-resistant microorganisms have become a common health threat in intensive care settings worldwide. Understanding antimicrobial resistance and the outcomes of these infections is crucial for addressing this issue. This study aimed to investigate the burden, antimicrobial resistance, and 28-day outcomes of nosocomial bloodstream infections in the intensive care unit.
View Article and Find Full Text PDFDose Optimization of Vancomycin in Pediatric Post-Cardiac Surgery Patients: A Population Pharmacokinetic Modeling Study.
Clin Pharmacokinet
December 2024
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Background And Objective: Vancomycin is a glycopeptide antibiotic used for the treatment of severe gram-positive infections. Despite decades of clinical experience, optimized dosing for vancomycin in pediatric populations still warrants further investigation. Patients admitted to the pediatric intensive care unit (PICU) after cardiac surgery are often treated with vancomycin in case of (suspected) infection.
View Article and Find Full Text PDFScreening and identification of antimicrobial peptides from the gut microbiome of cockroach Blattella germanica.
Microbiome
December 2024
MOE Key Laboratory of Bio-Intelligent Manufacturing, School of Bioengineering, Dalian University of Technology, Dalian, Liaoning, 116024, China.
Article Synopsis
- * Researchers identified and validated an AMP, named AMP1, which has broad-spectrum antibacterial activity and minimal toxicity to human cells, showing potential as a safer alternative to traditional antibiotics.
- * The study emphasizes the effective screening of natural AMPs and highlights AMP1's ability to affect bacterial cell wall synthesis and promote wound healing, suggesting it could be a viable option for clinical use.
Investigation of adsorption/desorption properties of vancomycin on ionic liquid modified magnetic activated carbon in aqueous solutions and cytotoxicity evaluation of synthesized nanoparticles.
Environ Sci Pollut Res Int
December 2024
Infectious Diseases and Tropical Medicine Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Zahedan, 98167-43463, Iran.
Effluents containing antibiotics raise concerns due to their potential to promote or sustain bacterial resistance and disrupt essential cycles and processes critical to aquatic ecology, agriculture, and animal farming. Vancomycin is a glycopeptide antibiotic, recognized as the treatment for cases in which other antibiotics are unsuccessful. The efficient elimination of antibiotics plays a crucial role in managing antibiotic pollution.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!